Vanda says EMA panel backs orphan drug designation for imsidolimab in generalized pustular psoriasis - VNDA News | RalliesVanda says EMA panel backs orphan drug designation for imsidolimab in generalized pustular psoriasis
V
VNDA• EMA panel backs orphan designation for imsidolimab
- EMA committee backed orphan drug designation for Vanda’s imsidolimab to treat generalized pustular psoriasis in the EU.
- FDA is reviewing an imsidolimab Biologics License Application for the same indication, with an action date of Dec. 12, 2026.
•
